Affordable Access

Access to the full text

Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics

Authors
  • Harvey, Christopher1
  • Elpek, Kutlu1
  • Duong, Ellen1
  • Simpson, Tyler1
  • Shu, ChengYi J1
  • Shallberg, Lindsey1
  • Wallace, Matthew1
  • Sathyanarayanan, Sriram1
  • Mabry, Robert1
  • Briskin, Michael1
  • Michaelson, Jennifer1
  • Gajewski, Thomas F2
  • 1 Jounce Therapeutics, Cambridge, MA, USA , Cambridge (United States)
  • 2 University of Chicago, Chicago, IL, USA , Chicago (United States)
Type
Published Article
Journal
Journal for ImmunoTherapy of Cancer
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Nov 04, 2015
Volume
3
Issue
Suppl 2
Identifiers
DOI: 10.1186/2051-1426-3-S2-O9
Source
Springer Nature
Keywords
License
Green
Report this publication

Statistics

Seen <100 times